We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

MedXY Editorial Team•Dec 23, 2025•Neurology
Chất ức chế BTKfenebrutinibmultiple sclerosisneuroimmunology

Highlights

Efficacy Results

Fenebrutinib demonstrated a 69% relative reduction in the total number of new T1 gadolinium-enhancing (Gd+) lesions compared to placebo (p=0.0022) at 12 weeks.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic ImplicationsThis review synthesizes evidence on IL-16-driven resistance to BTK inhibitors and chemoimmunotherapy in B-cell lymphomas, highlighting the IL-16/CD9/PI3K axis as a targetable epigenetically regulated survival pathway overcoming drug resistaSep 12, 2026Paramagnetic Rim Lesions as Predictors of Progression in Multiple Sclerosis: Insights from a 5-Year Longitudinal StudyParamagnetic rim lesions detected via MRI are associated with increased risk of disability progression independent of relapse activity and accelerated brain atrophy in multiple sclerosis, highlighting their role as prognostic biomarkers forAug 22, 2026Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-ScoresSerum neurofilament light chain (sNfL) z-score dynamics enhance monitoring of treatment response in relapsing multiple sclerosis (RMS), providing complementary predictive value for disease activity beyond conventional clinical and MRI assesAug 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Serum Glial Fibrillary Acidic Protein Dynamics in Multiple Sclerosis: Biomarker Insights into Disease Progression and Therapeutic ResponseSerum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.Aug 4, 2026
Multiple Sclerosis Does Not Appear to Worsen In-Hospital Outcomes After Cardiovascular Surgery, but Routine Home Discharge Is Less CommonA large US inpatient analysis found similar in-hospital mortality and complication rates after cardiovascular surgery in patients with and without multiple sclerosis, but patients with MS were less often discharged routinely home.Jun 11, 2026
Why Prevalence Is Rising Differently in Parkinson Disease, Multiple Sclerosis, and Motor Neuron DiseasesA large Sweden-France analysis suggests rising MS prevalence is mainly survival-driven, increasing MND prevalence reflects growing incidence, and PD prevalence rises modestly through mixed demographic and survival effects.Jun 9, 2026